Sensus Healthcare (NASDAQ:SRTS) Director Eric Sachetta Buys 2,500 Shares

Sensus Healthcare, Inc. (NASDAQ:SRTS) Director Eric Sachetta acquired 2,500 shares of the firm’s stock in a transaction that occurred on Thursday, November 13th. The stock was acquired at an average price of $4.50 per share, with a total value of $11,250.00. Following the completion of the acquisition, the director directly owned 133,113 shares of the company’s stock, valued at $599,008.50. This represents a 1.91% increase in their position. The transaction was disclosed in a filing with the SEC, which is available through this link.

Sensus Healthcare Trading Down 2.4%

NASDAQ SRTS traded down $0.10 during trading on Thursday, hitting $3.95. 105,466 shares of the company traded hands, compared to its average volume of 167,669. Sensus Healthcare, Inc. has a 12 month low of $3.03 and a 12 month high of $9.33. The business has a fifty day simple moving average of $3.44 and a 200 day simple moving average of $4.06. The company has a market capitalization of $64.80 million, a P/E ratio of -65.83 and a beta of 1.38.

Sensus Healthcare (NASDAQ:SRTS) last issued its quarterly earnings data on Thursday, November 6th. The company reported ($0.06) EPS for the quarter, beating analysts’ consensus estimates of ($0.12) by $0.06. Sensus Healthcare had a negative return on equity of 1.58% and a negative net margin of 2.26%.The business had revenue of $6.88 million for the quarter, compared to analyst estimates of $6.31 million. Equities research analysts predict that Sensus Healthcare, Inc. will post 0.32 EPS for the current fiscal year.

Wall Street Analyst Weigh In

SRTS has been the topic of several research analyst reports. Wall Street Zen raised Sensus Healthcare from a “sell” rating to a “hold” rating in a research report on Saturday, November 8th. Lake Street Capital cut their target price on Sensus Healthcare from $13.00 to $6.00 and set a “buy” rating for the company in a research note on Friday, August 8th. Weiss Ratings reaffirmed a “sell (d)” rating on shares of Sensus Healthcare in a research report on Wednesday, October 8th. HC Wainwright lowered their price target on shares of Sensus Healthcare from $12.00 to $8.00 and set a “buy” rating on the stock in a report on Tuesday, August 12th. Finally, Zacks Research raised shares of Sensus Healthcare from a “strong sell” rating to a “hold” rating in a report on Wednesday, October 22nd. Three equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the stock has an average rating of “Hold” and an average target price of $8.00.

Institutional Inflows and Outflows

Hedge funds have recently bought and sold shares of the stock. Kingstone Capital Partners Texas LLC bought a new position in shares of Sensus Healthcare during the second quarter valued at $3,170,000. Pacific Ridge Capital Partners LLC grew its holdings in shares of Sensus Healthcare by 26.1% in the 3rd quarter. Pacific Ridge Capital Partners LLC now owns 573,389 shares of the company’s stock worth $1,800,000 after purchasing an additional 118,628 shares during the last quarter. Acadian Asset Management LLC increased its position in shares of Sensus Healthcare by 35.3% during the 1st quarter. Acadian Asset Management LLC now owns 470,713 shares of the company’s stock worth $2,225,000 after purchasing an additional 122,746 shares in the last quarter. Divisadero Street Capital Management LP lifted its holdings in Sensus Healthcare by 39.5% during the 3rd quarter. Divisadero Street Capital Management LP now owns 452,897 shares of the company’s stock valued at $1,422,000 after purchasing an additional 128,224 shares during the last quarter. Finally, Geode Capital Management LLC boosted its position in Sensus Healthcare by 2.5% in the second quarter. Geode Capital Management LLC now owns 153,917 shares of the company’s stock valued at $730,000 after buying an additional 3,766 shares in the last quarter. 25.30% of the stock is currently owned by institutional investors and hedge funds.

Sensus Healthcare Company Profile

Sensus Healthcare, Inc, a medical device company, manufactures and sells radiation therapy devices to healthcare providers worldwide. The company uses superficial radiation therapy, a low-energy X-ray technology in its portfolio of treatment devices. It offers SRT-100, a photon X-ray low energy superficial radiotherapy system that provides patients an alternative to surgery for treating non-melanoma skin cancers, including basal cell and squamous cell skin cancers, as well as other skin conditions, such as keloids; and SRT-100 Vision, which provides the user with a superficial radiation therapy-tailored treatment planning application that integrates an embedded high frequency ultrasound imaging module, volumetric tumor analysis, beam margins planning, and dosimetry parameters.